New cell therapy takes on tough kidney cancer

NCT ID NCT06245915

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times

Summary

This study tests a new treatment called AB-2100 for people with advanced clear-cell kidney cancer that has come back after other therapies. The treatment uses specially designed immune cells to attack the cancer. The study aims to see if it is safe and whether it can shrink tumors. About 130 participants will take part across two phases.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Dana Farber Cancer Institue

    Boston, Massachusetts, 02215, United States

  • Huntsman Cancer Institute - Univ of Utah Health

    Salt Lake City, Utah, 84112, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic Hospital

    Phoenix, Arizona, 85054, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Perlmutter Cancer Center - NYU Langone Health

    New York, New York, 10016, United States

  • University of Iowa and Holden Comprehensive Cancer Center

    Iowa City, Iowa, 52242, United States

Conditions

Explore the condition pages connected to this study.